“Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo”, J of Skin, vol. 7, no. 6, p. s272, Nov. 2023, doi: 10.25251/skin.7.supp.272.